Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD133-CAR vector-transduced allogeneic T lymphocytes

A preparation of allogeneic peripheral blood T lymphocytes (PBTL) that have been genetically modified to express a chimeric antigen receptor (CAR) specific for the chimeric CD (cluster of differentiation) 133 antigen receptor, with potential immunostimulating and antineoplastic activities. Upon administration, anti-CD133-CAR vector-transduced allogeneic T lymphocytes specifically recognize and kill CD133-expressing tumor cells. CD133, a tumor associated antigen (TAA), is overexpressed on a variety of tumor cell types.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	allogeneic anti-CD133 CAR T cells allogeneic CART133

anti-CD133-CAR vector-transduced allogeneic T lymphocytes

Search NCI's Drug Dictionary